Study guide

15.3 Therapeutic Drug Monitoring

DHA Pharmacist Licensing Assessment PHO5481

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Licensing Pathway

1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan

2 Cardiovascular Pharmacology

2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents

3 Endocrine & Metabolic Pharmacology

3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents

4 Anti-Infective Pharmacology

4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars

5 CNS, Psychiatric & Pain Pharmacology

5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine

6 Respiratory, GI & Hematology Pharmacology

6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents

7 Pharmaceutical Care: Cardiometabolic Disease

7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management

8 Pharmaceutical Care: Respiratory, Rheumatology & Infection

8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship

9 Counseling, Monitoring & Special Populations

9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making

10 Pharmaceutical Calculations I

10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation

11 Pharmaceutical Calculations II

11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents

12 UAE Pharmacy Law & Regulation

12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity

13 Controlled Drugs, Ethics & Pharmacovigilance

13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal

14 Pharmacokinetics I: ADME

14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination

15 Pharmacokinetics II: Kinetics, Dosing & TDM

15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring

16 OTC Medicines & Self-Care

16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin

17 Medication Safety

17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition

18 Sterile & Nonsterile Compounding

18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding

19 Pharmaceutics, Biopharmaceutics & Toxicology

19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes

20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics

20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics

15.3 Therapeutic Drug Monitoring

Key Takeaways Explain This Topic AI

Therapeutic drug monitoring (TDM) adds value for drugs with a narrow therapeutic index, no easy clinical endpoint, nonlinear kinetics, or when toxicity or adherence is in question.

Digoxin samples must be drawn at least 6 hours post-dose (ideally 12–24 h); target 0.5–2.0 ng/mL, and hypokalaemia potentiates toxicity even at 'normal' levels.

Phenytoin (10–20 mg/L) is nonlinear and highly protein-bound — correct the measured level for low albumin before interpreting it.

Lithium is sampled as a standardised 12-hour post-dose level (target 0.6–1.0 mmol/L for maintenance); aminoglycosides use peak/trough or nomogram-based timing, and vancomycin is best monitored by AUC/MIC 400–600 rather than trough alone.

The commonest TDM disasters are sampling errors — wrong timing, lines contaminated with the drug, and adsorption to gel separator tubes — so always interpret a level against the dose history and the clinical picture.

Last updated: August 2026

When TDM Adds Value — and When It Does Not

Therapeutic drug monitoring (TDM) is the use of measured drug concentrations to individualise dosing. It is worth doing only when the result will change management. The classic indications are:

Narrow therapeutic index — the gap between effective and toxic concentrations is small (digoxin, lithium, phenytoin, theophylline, aminoglycosides, ciclosporin, tacrolimus)

No easy clinical endpoint — you cannot titrate seizure prophylaxis or transplant rejection prophylaxis by observation the way you titrate an antihypertensive to blood pressure

Nonlinear or unpredictable kinetics — phenytoin's saturation kinetics make dose–level relationships counter-intuitive

Suspected toxicity or non-adherence — a level distinguishes under-dosing from non-adherence and confirms or refutes toxicity

Major physiological change — renal failure, pregnancy, critical illness, or interacting drug started/stopped

Conversely, TDM is wasted effort when a reliable clinical or surrogate endpoint exists (blood pressure for antihypertensives, INR for warfarin, glucose for antidiabetics) or when the assay cannot be timed or interpreted correctly. A level drawn at the wrong time is worse than no level, because it invites a confident wrong decision.

Reference Targets and Sample Timing

Drug Target range Sample timing Key notes

Digoxin 0.5–2.0 ng/mL (lower end, 0.5–0.9, preferred in heart failure) ≥6 h post-dose; ideally 12–24 h Early samples read falsely high — distribution into tissue is incomplete; hypokalaemia potentiates toxicity even at in-range levels

Lithium 0.6–1.0 mmol/L maintenance (up to 1.2 acutely) Standardised 12-h post-dose sample Check renal and thyroid function; dehydration and NSAIDs raise levels

Phenytoin 10–20 mg/L Trough at steady state (may take 2+ weeks) Nonlinear; 90% albumin-bound — correct for hypoalbuminaemia

  • Valproate 50–100 mg/L Trough Poor level–effect correlation; interpret with the clinical picture
  • Carbamazepine 4–12 mg/L Trough Autoinduction lowers levels over the first weeks of therapy

Theophylline 10–20 mg/L Steady-state sample (timing depends on formulation) Nonlinear at higher levels; smoking induces, ciprofloxacin inhibits clearance

Aminoglycosides (gentamicin/tobramycin) Conventional: peak 5–10 mg/L, trough <2 mg/L Peak ~30–60 min after infusion ends; trough pre-dose Once-daily regimens use a single timed level interpreted against the Hartford nomogram (e.g. 6–14 h post-dose) rather than classic peak/trough targets

Vancomycin AUC/MIC 400–600 (MIC assumed 1 mg/L) Two levels at steady state for AUC estimation, or Bayesian software AUC-guided dosing is preferred over the older trough-only target of 15–20 mg/L

Ciclosporin / tacrolimus Assay- and indication-specific C0 trough (pre-dose, 12 h) CYP3A substrates — levels soar with azole antifungals and crash with enzyme inducers; grapefruit juice raises levels

Sampling Errors That Ruin Good Assays

Wrong timing — the single most frequent error. A digoxin level drawn 2 hours post-dose can read twice the interpretable value because distribution is incomplete; an aminoglycoside 'trough' drawn mid-interval is meaningless. Document the exact dose and sample times on the request.

Contaminated line — blood drawn from the same cannula used to infuse the drug (classic with vancomycin and aminoglycosides) reads astronomically high. Draw from the opposite limb or after an adequate flush.

Gel separator tubes — some drugs adsorb to the serum-separator gel over time, falsely lowering results (phenytoin is the textbook concern); use the tube type the laboratory specifies and separate promptly.

Sampling before steady state — a level taken two half-lives into a new regimen reflects a concentration still climbing; the apparent 'subtherapeutic' result tempts an unnecessary dose increase.

Interpreting a Level in Clinical Context

A concentration is a number in search of a story. Ask: was it steady state? Was timing correct? Does the patient look toxic or controlled? Two worked situations illustrate this. First, digoxin with hypokalaemia : a level of 1.8 ng/mL — technically in range — in a patient with potassium 2.8 mmol/L, nausea and new arrhythmia is toxicity; hypokalaemia increases digoxin's binding to Na⁺/K⁺-ATPase, so the tissue effect exceeds what the number suggests. Correct the potassium and treat the patient, not the assay. Second, phenytoin with hypoalbuminaemia : only unbound drug is active, and in low-albumin states (uraemia, pregnancy, critical illness) the measured total level underestimates the active fraction. The Sheiner–Tozer correction adjusts it:

C_adjusted = C_measured / (0.2 × albumin + 0.1)

with albumin in g/dL. Worked example: measured total phenytoin 8 mg/L with albumin 2.0 g/dL gives 8 / (0.2 × 2.0 + 0.1) = 8 / 0.5 = 16 mg/L — an apparently subtherapeutic level is actually mid-therapeutic, and a knee-jerk dose increase could have caused toxicity.

Communicating and Acting on Dose Changes

Make one change at a time, in proportion for linear drugs and in small increments for nonlinear ones, and state the rationale in the record: current regimen, measured level with sample time, target, new regimen, and the date for the repeat level — after 4–5 half-lives for linear drugs, and after two or more weeks for phenytoin. Tell the patient exactly what changed and which toxicity or under-treatment symptoms should trigger early review. TDM only improves outcomes when the loop — sample, interpret, adjust, re-sample — is closed.